A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase

Ashleigh Shannon1, Véronique Fattorini1, Bhawna Sama1

  • 1Architecture et Fonction des Macromolécules Biologiques, CNRS and Aix Marseille Université, UMR 7257, Polytech Case 925, 13009, Marseille, France.

Nature Communications
|February 3, 2022
PubMed

Insights

The antiviral AT-527, converted to AT-9010, inhibits SARS-CoV-2 by terminating RNA synthesis and blocking NiRAN activity. This dual mechanism offers a promising COVID-19 treatment strategy.

Area of Science:

  • Virology
  • Structural Biology
  • Drug Discovery

Background:

  • Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2) causes COVID-19.
  • Antiviral therapies targeting viral replication are crucial for managing COVID-19.
  • The guanosine analog AT-527 is a potential therapeutic agent that has advanced to phase III clinical trials.

Purpose of the Study:

  • To elucidate the structural basis of AT-527's antiviral activity against SARS-CoV-2.
  • To investigate the interaction of AT-527's active metabolite, AT-9010, with the viral RNA-dependent RNA polymerase (RdRp).
  • To understand the dual mechanism of action of AT-527.

Main Methods:

  • Cryo-electron microscopy (cryo-EM) was used to determine the structure of the SARS-CoV-2 nsp12-nsp7-nsp82-RNA complex.
  • The structure revealed the binding sites and interactions of AT-9010 within the nsp12 enzyme.
  • Biochemical assays were employed to assess the inhibition of nucleotidyltransferase activity.

Main Results:

  • A 2.98 Å cryo-EM structure showed AT-9010 bound at three sites on nsp12.
  • One AT-9010 molecule was incorporated into the RNA strand, causing chain termination due to its modified ribose.
  • A second AT-9010 molecule bound to the NiRAN domain, competitively inhibiting its nucleotidyltransferase activity.

Conclusions:

  • AT-527, via AT-9010, exhibits a dual mechanism of action against SARS-CoV-2.
  • The drug terminates viral RNA synthesis by inhibiting the RdRp active site.
  • AT-9010 also inhibits the NiRAN domain's nucleotidyltransferase activity, providing a potent antiviral strategy.

Related Concept Videos

Leaky Scanning02:28

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.3K
Bacterial RNA Polymerase00:43

Bacterial RNA Polymerase

9.2K
RNA Polymerase II Accessory Proteins02:36

RNA Polymerase II Accessory Proteins

Proteins that regulate transcription can do so either via direct contact with RNA Polymerase or through indirect interactions facilitated by adaptors, mediators, histone-modifying proteins, and nucleosome remodelers. Direct interactions to activate transcription is seen in bacteria as well as in some eukaryotic genes. In these cases, upstream activation sequences are adjacent to the promoters, and the activator proteins interact directly with the transcriptional machinery. For example, in...
9.7K
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.0K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.6K